Insilico to present Phase 1 trial data for AI-designed cancer drug at ESMO 2026
Insilico Medicine announced that first-in-human Phase 1 trial data for ISM6331 has been accepted for a Rapid Oral presentation at the European Society for Medical Oncology Congress 2026, scheduled for 23-27 October 2026, in Madrid, Spain. The Rapid Oral session is listed as Developmental Therapeutic
<p>Insilico Medicine announced that first-in-human Phase 1 trial data for ISM6331 has been accepted for a Rapid Oral presentation at the European Society for Medical Oncology Congress 2026, scheduled for 23-27 October 2026, in Madrid, Spain. The Rapid Oral session is listed as Developmental Therapeutic</p>